Lysosomal Membrane Permeabilization by Targeted Magnetic Nanoparticles in Alternating Magnetic Fields
Source abstract
Abstract
Lysosomal death pathways are being explored as alternatives of overcoming cancer tumor resistance to traditional forms of treatment. Nanotechnologies that can selectively target and induce permeabilization of lysosomal compartments in cells could become powerful medical tools. Here we demonstrate that iron oxide magnetic nanoparticles (MNPs) targeted to the epidermal growth factor receptor (EGFR) can selectively induce lysosomal membrane permeabilization (LMP) in cancer cells overexpressing the EGFR under the action of an alternating magnetic field (AMF). LMP was observed to correlate with the production of reactive oxygen species (ROS) and a decrease in tumor cell viability. Confocal microscopy images showed an increase in the cytosolic activity of the lysosomal protease cathepsin B. These observations suggest the possibility of remotely triggering lysosomal death pathways in cancer cells through the administration of MNPs which target lysosomal internalization pathways and the application of AMFs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Calcium signaling and nucleotide metabolism · Cellular transport and secretion · Autophagy in Disease and Therapy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, University of Puerto Rico, Mayaguez, Puerto Rico 00681, United States
Industrial Biotechnology Program, University of Puerto Rico, Mayaguez, Puerto Rico 00681, United States
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida 32611, United States
Department of Chemical Engineering, University of Florida, Gainesville, Florida 32611, United States
References (51)
Show source-provided references
1. Gillet J. P. · Methods Mol. Biol. · 2010 · 596 · 4710.1007/978-1-60761-416-6_4 ↗
2. Gottesman M. M. · Annu. Rev. Med. · 2002 · 53 · 61510.1146/annurev.med.53.082901.103929 ↗
3. Calcagno A. M. · J. Natl. Cancer Inst. · 2010 · 102 · 163710.1093/jnci/djq361 ↗
4. Gottesman M. M. · Nat. Rev. Cancer · 2002 · 2 · 4810.1038/nrc706 ↗
5. Tolomeo M. · Curr. Med .Chem. Anticancer Agents · 2002 · 2 · 38710.2174/1568011024606361 ↗
6. Maione P. · Oncologist · 2006 · 11 · 27410.1634/theoncologist.11-3-274 ↗
7. Rodriguez-Enriquez S. · Mol. Nutr. Food Res. · 2009 · 53 · 2910.1002/mnfr.200700470 ↗
8. Diaz A. · Cancers · 2011 · 3 · 333110.3390/cancers3033331 ↗
9. Bao S. · Nature · 2006 · 444 · 75610.1038/nature05236 ↗
10. Ishikawa F. · Nat. Biotechnol. · 2007 · 25 · 131510.1038/nbt1350 ↗
11. Kirkegaard T. · Biochim. Biophys. Acta · 2009 · 1793 · 74610.1016/j.bbamcr.2008.09.008 ↗
12. Erdal H. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 19210.1073/pnas.0408592102 ↗
13. Jaattela M. · Oncogene · 2004 · 23 · 274610.1038/sj.onc.1207513 ↗
14. Lin C. W. · Photochem. Photobiol. · 1993 · 58 · 8110.1111/j.1751-1097.1993.tb04907.x ↗
15. Ostenfeld M. S. · Autophagy · 2008 · 4 · 48710.4161/auto.5774 ↗
16. Wan F. Y. · Arch. Biochem. Biophys. · 2002 · 404 · 28510.1016/S0003-9861(02)00280-1 ↗
17. Wan F. Y. · Arch. Biochem. Biophys. · 2002 · 402 · 26810.1016/S0003-9861(02)00083-8 ↗
18. Kornhuber J. · J. Cell Physiol. · 2010 · 224 · 15210.1002/jcp.22112 ↗
19. Foghsgaard L. · J. Cell Biol. · 2001 · 153 · 99910.1083/jcb.153.5.999 ↗
20. Ostenfeld M. S. · Cancer Res. · 2005 · 65 · 897510.1158/0008-5472.CAN-05-0269 ↗
21. Xiang J. · Proc. Natl. Acad. Sci. U.S.A. · 1996 · 93 · 1455910.1073/pnas.93.25.14559 ↗
22. Ullio C. · J. Lipid Res. · 2012 · 53 · 113410.1194/jlr.M022384 ↗
23. Taha T. A. · Biochim. Biophys. Acta · 2006 · 1758 · 202710.1016/j.bbamem.2006.10.018 ↗
24. Suzuki E. · Proc. Natl. Acad. Sci. U.S.A. · 2004 · 101 · 1478810.1073/pnas.0406536101 ↗
25. Amstad E. · Nano Let.t · 2011 · 11 · 166410.1021/nl2001499 ↗
26. Creixell M. · ACS Nano · 2011 · 5 · 712410.1021/nn201822b ↗
27. Rocha-Lima C. M. · Cancer Control · 2007 · 14 · 29510.1177/107327480701400313 ↗
28. Roepstorff K. · Traffic · 2009 · 10 · 111510.1111/j.1600-0854.2009.00943.x ↗
29. Sorkin A. · Exp. Cell Res. · 2008 · 314 · 309310.1016/S0014-4827(08)00404-7 ↗
30. Latorre M. · P. R. Health Sci. J. · 2009 · 28 · 227
31. Jordan A. · Int. J. Hyperthermia · 2009 · 25 · 51210.3109/02656730903183445 ↗
32. Creixell M. · J. Mater. Chem. · 2010 · 20 · 853910.1039/c0jm01504k ↗
33. Kurz T. · FEBS J. · 2006 · 273 · 310610.1111/j.1742-4658.2006.05321.x ↗
34. Lin Y. · Invest. Ophthalmol. Visual Sci. · 2010 · 51 · 648310.1167/iovs.10-5410 ↗
35. Leist M. · Cell Death Differ. · 2001 · 8 · 32410.1038/sj.cdd.4400859 ↗
36. Guicciardi M. E. · Oncogene · 2004 · 23 · 288110.1038/sj.onc.1207512 ↗
37. Vertrees R. A. · Ann. Thorac Surg. · 2000 · 69 · 167510.1016/S0003-4975(00)01421-1 ↗
38. Hiramoto Y. · J. Surg. Oncol. · 1989 · 40 · 17010.1002/jso.2930400307 ↗
39. Tomasini M. D. · Exp. Biol. Med. · 2010 · 235 · 18110.1258/ebm.2009.009187 ↗
40. Huang H. · Nat. Nanotechnol. · 2010 · 5 · 60210.1038/nnano.2010.125 ↗
41. Polo-Corrales L. · J. Appl. Phys. · 2012 · 111 · 07B33410.1063/1.3680532 ↗
42. Min K. A. · ACS Nano · 2013 · 7 · 216110.1021/nn3057565 ↗
43. Shen J.-M. · Pharmacol. Res. · 2013 · 70 · 10210.1016/j.phrs.2013.01.009 ↗
44. Chertok B. · J. Controlled Release · 2011 · 155 · 39310.1016/j.jconrel.2011.06.033 ↗
45. Li S. · Cancer Cell · 2005 · 7 · 30110.1016/j.ccr.2005.03.003 ↗
46. Trapp S. · Eur Biophys J · 2008 · 37 · 131710.1007/s00249-008-0338-4 ↗
47. Hallifax D. · Drug Metab. Dispos. · 2007 · 35 · 132510.1124/dmd.107.015131 ↗
48. Daniel W. A. · Eur. Neuropsychopharmacol. · 1999 · 9 · 48310.1016/S0924-977X(99)00034-6 ↗
49. Chertok B. · Biomaterials · 2011 · 32 · 624510.1016/j.biomaterials.2011.05.004 ↗
50. Jordan A. · J. Magn. Magn. Mater. · 2001 · 225 · 11810.1016/S0304-8853(00)01239-7 ↗
51. Creixell M. · J. Magn. Magn. Mater. · 2010 · 322 · 224410.1016/j.jmmm.2010.02.019 ↗